Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07476001 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07476001 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 12 participants, below the 198-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07476001, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer. Participants will be asked to spend about 6 months in this study. Participants will take study drug for 3.5 months.
Conditions Studied
Interventions
- DRUG Testosterone cypionate (Tc)
- DRUG ADT with Luteinizing hormone-releasing hormone (LHRH) analog
- DRUG PSMA-617
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07476001
The ClinicalTrials.gov registry entry for NCT07476001 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (94% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Testosterone cypionate (Tc) is the first listed.
NCT07476001 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07476001 about?
NCT07476001 is a clinical study titled "Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC". The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer. Participants will be asked to spend about 6 months in this study. Participants will take study drug for 3.5...
What is the current status of trial NCT07476001?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2026-03. Estimated completion is 2027-09.
What conditions does trial NCT07476001 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.
What interventions are being tested in trial NCT07476001?
The interventions under investigation include: Testosterone cypionate (Tc) (DRUG), ADT with Luteinizing hormone-releasing hormone (LHRH) analog (DRUG), PSMA-617 (DRUG).
Who is sponsoring clinical trial NCT07476001?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07476001 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
RECRUITING · Phase 2
-
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
RECRUITING · Phase 2
-
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.